News
EYPT
3.620
-0.82%
-0.030
These beaten-down stocks could bounce back in January, if history is any guide
MarketWatch · 5d ago
Weekly Report: what happened at EYPT last week (0914-0918)?
Weekly Report · 6d ago
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 09/18 12:01
Weekly Report: what happened at EYPT last week (0907-0911)?
Weekly Report · 09/14 09:12
EyePoint updates DURAVYU Phase 3 wet AMD data
TipRanks · 09/10 11:31
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)
TipRanks · 09/10 10:30
Weekly Report: what happened at EYPT last week (0831-0904)?
Weekly Report · 09/07 09:11
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
TipRanks · 09/05 09:01
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Benzinga · 09/02 15:32
EyePoint drops as TD Cowen becomes latest to downgrade on late-stage trial setback
Seeking Alpha · 09/02 14:09
Sirius XM upgraded, Toast downgraded: Wall Street’s top analyst calls
TipRanks · 09/02 13:55
EyePoint Price Target Cut to $4.00/Share From $20.00 by TD Cowen
Dow Jones · 09/02 13:30
EyePoint Cut to Hold From Buy by TD Cowen
Dow Jones · 09/02 13:30
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
Benzinga · 09/02 13:21
Video: Dell rises as AI demand drives ‘blowout’ quarter
TipRanks · 09/02 13:10
EyePoint downgraded to Hold from Buy at TD Cowen
TipRanks · 09/02 09:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)
TipRanks · 09/02 04:30
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Barchart · 09/01 19:00
Weekly Report: what happened at EYPT last week (0824-0828)?
Weekly Report · 08/31 09:12
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
Barchart · 08/28 13:11
More
Webull provides a variety of real-time EYPT stock news. You can receive the latest news about EyePoint through multiple platforms. This information may help you make smarter investment decisions.
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.